Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D2.380 - Incidental Low Serum IgE: A Marker of Underlying Inborn Errors of Immunity?
D2.383 - Ocular Cicatricial Pemphigoid: Experience with Methotrexate immunosuppression in a case series from Mar del Plata, Argentina
D2.389 - Optic disc swelling in Common variable immunodeficiency, two cases from a small U.K. cohort
D2.381 - Early Infantile Immune Dysregulation with an Atopic Phenotype: A Case of Genetically Confirmed Otulipenia
D2.382 - Contribution of Clinical and Laboratory Findings to Genetic Testing Decisions and Diagnostic Yield in Patients with Suspected Primary Immunodeficiency
D2.384 - Early inflammatory manifestations in a child carrying a heterozygous TREX1 variant: possible evolving interferonopathy?
D2.385 - Granulomatous and Lymphocytic Inerstitial Lung Disease (GLILD) in Common Variable Immunodeficiencies (CVIDs): preliminary results of a multicenter retrospective observational study
D2.386 - Intravenous Immunoglobulin–Associated Severe Prolonged Neutropenia: A Rare but Life-Threatening Complication in Primary Immunodeficiency
D2.387 - Hemophagocytic Lymphohistiocytosis and Progressive Neurological Involvement in Two Patients with Severe Congenital Neutropenia Due to VPS45 Deficiency
D2.388 - Is Sarcoidosis a preliminary feature of Inborn Errors of Immunity?
D2.390 - Evaluation of CD4⁻ CD8⁻ T Cell Population According to Patient Diagnostic Groups: A Single-Center Study
D2.391 - Assessment of Small Airway Dysfunction by Impulse Oscillometry in Patients with CVID and Selective IgA Deficiency
D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial
D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial
D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial
D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study
D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study
D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis
D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial
D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download